Trinity adds $9.5M in debt relief as Perceptive props up strained balance sheet
What's the deal? Trinity amended its credit agreement with lender Perceptive Credit Holdings III, LP, securing $9.5 million in financing to ease liquidity constraints. The package combines $4 million in new debt with $5.5 million of interest added to the existing loan, letting the diagnostics company defer cash outflows. Trinity makes point-of-care and clinical laboratory testing systems.
Why now? The November amendment, dated November 6, follows an August deal with the same lender that provided $7 million, mostly capitalized interest. Both rounds waived liquidity-covenant requirements; the latest covers noncompliance from June through October.
What else changed? Trinity lowered the minimum conversion price of its senior convertible note to $10.00 per American Depositary Share and cut the exercise price on warrants held by Perceptive funds II and III to $5.90. The changes ease Perceptive's path to equity but raise potential dilution for existing shareholders.
What could go wrong? Capitalizing interest preserves short-term cash but swells overall debt, which stood at roughly $115 million as of August. The loan matures in January 2027, and subsidiaries including Clark Laboratories, Biopool U.S., Primus Corporation, MarDx Diagnostics, IMMCO DiagnosticsDealroom has a profile for this one. Try Dealroom →, and TRIB Biosensors act as guarantors — a sign of how heavily the company's assets are encumbered.
The signal: This is a creditor-supported bridge, not a funding comeback. Perceptive is keeping Trinity afloat while repositioning itself to convert debt into equity on better terms — relief for now, pressure ahead of a looming maturity.
Read more: panabee.com
Image credit: jurvetson
